A Double-Blind, Randomized,Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 for the Treatment of Pain in Osteoarthritis of the Knee.

Trial Profile

A Double-Blind, Randomized,Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 for the Treatment of Pain in Osteoarthritis of the Knee.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs FX 005 (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 30 May 2012 Primary endpoint 'Western-Ontario-and-McMaster-Universities-Osteoarthritis-Index' has been met, according to a Flexion Therapeutics media release.
    • 30 May 2012 Planned number of patients changed from 140 to 104 as reported by a Flexion Therapeutics media release.
    • 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top